Nifty 50 closed at 23,123, down 1% on the day, sitting below its 200-day average and 12.2% off its 52-week high. Decliners swamped advancers 1,822 to 401, new lows outpaced new highs 123 to 94, and only 32% of NSE stocks are above their 200-day average — the tape remains weak. The regime has been weak-but-recovering for a fifth consecutive day, and the near-term read is neutral-to-up, so the index-level pressure and the underlying Stage-2 expansion are pulling in opposite directions right now.
Rotation and sector read
On the day, the least-damaged sectors were Health Care, Consumer Staples and Communication Services — all negative, but the relative holdouts on a broad down tape. That three-month picture is more instructive: Industrials leads all sectors at +10.5%, followed by Health Care at +9.3% and Utilities at +8.1%. Financials and Energy are the three-month laggards at -9.8% and -8.3% respectively, though Energy is one of the sectors where the Stage-2 cohort has been expanding fastest over the last 20 days, alongside Consumer Staples and Materials — a sign that stock-level recovery within those sectors is quietly broadening even as the index-level numbers remain soft.
Breadth beneath the surface
Despite the headline weakness, 82 stocks moved from Stage 1 into Stage 2 over the last five days against only 8 moving from Stage 2 into Stage 3 — a net of 74 fresh advances. The overall Stage-2 share now stands at 23.4% of the NSE universe, and that cohort has widened by 3.7 over five days, 9.3 over 20 days and 10.6 over 60 days. Twenty golden crosses were recorded today against just two death crosses. The breadth label is narrow but improving — the index is not confirming what is happening at the stock level, which is precisely the kind of divergence the screener is designed to surface. On the volume side, OCCL Ltd in Materials moved 16.2% on nearly 48 times normal volume, Creative Newtech Ltd in IT gained 14% on 32.5 times volume, and Tci Finance Ltd in Financials added 20% on 20 times volume — all flagged as standout high-volume movers by the screener.
What cleared the screen today
Among today's fresh breakouts, Premier Explosives Ltd and Supriya Lifescience Ltd both cleared with a setup score of 8.4 — the highest in today's breakout list — from the Materials and Health Care sectors respectively. Panama Petrochem Ltd also screens from Materials at 7.3. In the sustained-setup list, Stylam Industries Ltd leads at 9.8, with Venus Remedies Ltd and Bliss GVS Pharma Ltd close behind at 9.6 each — all three have held clean Stage-2 structures through the recent index weakness. The full breakout and fresh-transition tables are below.
| Stock | Sector | Setup | % 1D |
|---|---|---|---|
| Premier Explosives Ltd | Materials | 8.4 | +0.3% |
| Supriya Lifescience Ltd | Health Care | 8.4 | -3.0% |
| Panama Petrochem Ltd | Materials | 7.3 | -2.9% |
| Bal Pharma Ltd | Health Care | 6.9 | -1.4% |
| B&B Triplewall Containers Ltd | Materials | 6.7 | +6.9% |
| Hindustan Oil Exploration Company Ltd | Energy | 6.4 | +1.4% |
| GMR Airports Ltd | Industrials | 5.5 | -1.7% |
| Bharat Gears Ltd | Consumer Discretionary | 4.5 | -3.7% |
| Sector | 1D | 1M | 3M | RS | Stage 2 |
|---|---|---|---|---|---|
| Health Care | -0.2% | +1.4% | +9.3% | 72 | 31% |
| Consumer Staples | -0.4% | -5.9% | -1.8% | 54 | 32% |
| Communication Services | -0.9% | +1.5% | +6.6% | 65 | 11% |
| Utilities | -1.3% | -1.2% | +8.1% | 67 | 26% |
| Financials | -1.3% | -8.7% | -9.8% | 58 | 21% |
| Information Technology | -1.6% | -2.4% | -2.3% | 39 | 18% |
| Consumer Discretionary | -1.6% | -4.8% | -1.0% | 65 | 19% |
| Energy | -1.9% | -9.4% | -8.3% | 61 | 46% |
| Materials | -1.9% | -3.6% | +3.8% | 71 | 27% |
| Industrials | -2.1% | -1.7% | +10.5% | 67 | 25% |
| Real Estate | -2.5% | -8.5% | -1.7% | 40 | 9% |
Work the same data live: open the full stock screener, watch the live market dashboard, or check the market-timing read. New to the method? Start with the four stages.
Stage2Stocks is an educational stage-analysis screener. These wraps describe what the screen shows across NSE cash equities — they are not investment advice, recommendations, or buy/sell calls. Always do your own research.